NanoViricides to Present Antiviral Drug Pipeline at Spartan Capital Investor Conference

NanoViricides Inc. (NYSE American: NNVC), a clinical-stage developer of broad-spectrum antiviral drugs, will present at the Spartan Capital Investor Conference on November 3, 2025. The company specializes in creating special purpose nanomaterials for antiviral therapy using its proprietary nanoviricide technology platform licensed from TheraCour Pharma Inc.

The company's lead drug candidate, NV-387, represents a significant advancement in antiviral treatment as a broad-spectrum therapeutic planned for development against multiple respiratory viral infections including RSV, COVID-19, Long COVID, and influenza, as well as MPOX/Smallpox infections. This multi-target approach could potentially address the challenge of viral escape that often limits the effectiveness of traditional antiviral medications. The company is currently focused on advancing NV-387 into Phase II human clinical trials, though it cannot project exact timelines for Investigational New Drug applications due to dependence on external collaborators.

NanoViricides' second advanced drug candidate, NV-HHV-1, targets the treatment of shingles, demonstrating the platform's versatility across different viral families. The company's business model, established in 2005, is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of particular viruses. Through this arrangement, NanoViricides holds worldwide exclusive perpetual licenses for several drugs targeting human viral diseases including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza, Dengue viruses, Ebola/Marburg viruses, and certain Coronaviruses.

The company's technology platform and programs are based on the TheraCour nanomedicine technology, which TheraCour licenses from AllExcel. This foundation provides the scientific basis for developing novel antiviral treatments that could potentially address multiple viral threats with a single therapeutic approach. The company also maintains development programs against additional viral diseases including oral and genital Herpes, viral eye diseases such as EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, and seasonal Influenza.

NanoViricides intends to obtain additional licenses for RSV, Poxviruses, and/or Enteroviruses if initial research proves successful. The company's presentation at the investor conference comes at a time when global health systems continue to face challenges from emerging and re-emerging viral threats, highlighting the ongoing need for innovative antiviral solutions. The development of broad-spectrum antiviral platforms like NanoViricides' technology could potentially transform how healthcare systems prepare for and respond to viral outbreaks by providing treatments effective against multiple related viruses.

As with all pharmaceutical development, the company acknowledges that the path to drug approval is extremely lengthy and requires substantial capital investment. There can be no assurance that any of the company's pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development or that successful laboratory results will lead to successful clinical trials or commercial products. The company's latest news and updates are available through its newsroom at https://ibn.fm/NNVC.